|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0000 - 0.0000|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
3 Carbon will advise them on quality assurance standards for light hydrocarbon-based manufacturing and extraction methods. CannabisWise is an accreditation program established by the BC based National Institute for Cannabis Health and Education (NICHE) earlier this year in response to Canada’s plan to legalize cannabis. 3 Carbon Extractions CEO Phillip Kwong said, “We are excited to be collaborating with this exciting initiative.
VANCOUVER, British Columbia, Sept. 11, 2018-- Veritas Pharma Inc. is pleased to announce that 3 Carbon Extractions Inc., an industry leader in regulatory compliant cannabis hydrocarbon extraction solutions, ...
VANCOUVER, British Columbia, Sept. 05, 2018-- Veritas Pharma Inc. is pleased to announce that its subsidiary, 3 Carbon Extractions Inc., has completed an exclusive marketing rights relationship with ExtractionTek ...
Lui Franciosi commented: “We are very pleased to welcome Mr. Roseborough to Veritas’ Board of Directors. Mr. Roseborough brings a wealth of talent and expertise to the Company. He’s currently the CEO of SunVault Energy Inc. (SVLT) in Kelowna, B.C., which focuses on bringing cost effective energy generation and storage to the solar industry. He previously held the position as a Start-up Lead Executive for Dow Corning’s $1.2 billion Semiconductor plant in Clarksville, Tennessee.
Under the terms of the Agreement as previously announced on April 16, 2018, Veritas has invested $300,000 US into 3 Carbon and issued 1,500,000 common shares of Veritas at a deemed price of $0.40 per share to the shareholders of 3 Carbon. The cash consideration will be used to build a scalable extraction facility at a location to be determined by the board of Veritas.
VANCOUVER, British Columbia, Aug. 15, 2018-- Veritas Pharma Inc. is pleased to announce that it has signed a Memorandum of Understanding with IsCann Group Limited located in Be'er Tuvya, Israel with the ...
VANCOUVER, British Columbia, Aug. 13, 2018-- Veritas Pharma Inc. is pleased to announce that it has entered into a Memorandum of Understanding with the Chamber of Commerce, Industry, Services and Tourism ...
VANCOUVER, British Columbia, Aug. 08, 2018-- Veritas Pharma Inc. is pleased to announce that Clearstream Banking, a major central securities depository based in Frankfurt, Germany, which announced on June ...
VANCOUVER, British Columbia, July 27, 2018-- Veritas Pharma Inc. is pleased to announce that effective June 25, 2018, it cancelled a total of 3,272,000 incentive stock options granted under the Company’ ...
Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F), (“Veritas” or the “Company”) is pleased to announce that it has signed an Intellectual Property Sharing Agreement (“Joint IP”) with Sativa Investments PLC (“Sativa”) (NEX:SATI), UK’s first medicinal cannabis investment fund. Veritas through its subsidiary company, Cannevert Therapeutics Ltd., will apply its pharmacological methods on cannabis strain lead selection to assist Sativa’s application to the UK Home Office Drugs Licensing and Compliance Unit for a medicinal cannabis growing license.
Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F) (“Veritas” or the “Company”) is pleased to announce that Mr. Filios Theodorou has been appointed as its business development agent in Cyprus. Currently, medical cannabis is legal in Cyprus, nonetheless doctors may only prescribe it to patients suffering from specific ailments, typically as a last resort and strictly for palliative care.
In this article, I’m going to take a look at Veritas Pharma Inc’s (DB:2VP) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
CALGARY, Feb. 28, 2018 /CNW/ - BioCan Technologies Inc. ("BioCan" or the "Company") is pleased to announce that it has entered into a Memorandum of Understanding ("MoU") with Veritas Pharma Inc. ("Veritas") (CSE:VRT) (VRTHF) (Frankfurt: 2VP) to collaborate with Veritas on an exclusive basis to undertake further investigations of cannabis strains being developed by the research arm of Veritas, Cannevert Therapeutics Ltd. ("CTL"). The focus will be to optimize the genetics of their cannabis plants for scientific and clinical testing over the next two years. Pursuant to the MoU, definitive agreements in respect of the transactions contemplated in the MoU are expected to be executed by the parties on or before July 31, 2018. BioCan's CEO, Trevor Peters, stated "We are pleased to be working with Veritas and their scientific teams to develop medically relevant cannabis strains and cannabinoid formulations with optimal therapeutic properties.